Overview

• The investigational therapy, bemdaneprocel, aims to restore dopamine function by transplanting lab-grown cells into the brain.
• Bayer targets initial study readouts around 2027, with potential regulatory submissions to follow if outcomes are positive.
• A separate AskBio gene-therapy for Parkinson’s remains in Phase 2, supported by AAV vector production at Bayer’s Viralgen site in San Sebastián.
• CEO Bill Anderson and other leaders voiced strong optimism about the programs’ potential while noting the inherent risks of late-stage trials.
• The push reflects high stakes for Bayer as it contends with patent expiries and prior setbacks, including the failed 2023 Asundexian study and Monsanto-related liabilities.